Interestingly, multiple somatic mutations in FEM1C were reported to occur in different cancers, and some affect residues responsible for substrate binding: Asp77Tyr (identified in colorectal cancer), Asp77Gly (identified in uterine corpus endometrioid carcinoma) and Glu191Gln (identified in bladder urothelial carcinoma) (42). Here, FEM1C is linked to endometrial endometrioid adenocarcinoma.